Hale & Tempest India UKIBC Briefing Dr. Brian W Tempest UK India Business Council Manchester 10 March 2011

Hale & Tempest Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until He was then Chief Mentor and Non Executive Director until He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also been Regional Director, Far East for Glaxo where he was responsible for businesses in Japan, China, Korea, and Taiwan. Brian has worked in the Pharmaceutical Industry for the last 39 years and led Healthcare businesses in North America, South America, Europe, Africa, Middle East, Asia and India. He has also led sessions at Investor Meetings across Asia, Europe and USA. He is now an International Advisor to MAPE – India, Religare -India and UNCTAD - Switzerland. In addition he is a member of the SCRIP Global awards panel. Brian speaks at global conferences on the Challenge from India and China and more information on these presentations can be found on his website Brian has a PhD in Polymer Chemistry from Lancaster University and is a member of the Royal Society of Medicine, the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman of Hale & Tempest Co Ltd.

Hale & Tempest  President, CEO, Non Exec Indian Pharma Company - Ranbaxy  One of the few westerners to have a lead a Sensex 50 blue chip Indian MNC  Resided in India , bought & sold homes in Delhi, today an Indian pensioner and Indian tax payer  Non Exec Chairman, Indian Investment Bank, Religare Capital Markets  Non Exec Director, Indian Diagnostic Company, SRL  Non Exec Director, Indian Healthcare Company Fortis Global Healthcare India Briefing

Hale & Tempest The View from Davos Source – FT

Hale & Tempest The Indian Education Advantage

Hale & Tempest The Indian Education Advantage Engineers/Science graduates pa– India 0.7m, China 0.5m, EU 0.5m, USA 0.4m, Japan 0.3m

Hale & Tempest Indian Businesses are Global Pharma Exports by Country

Hale & Tempest Indian Pharma Sales by Geography Source Ranbaxy 2006 $ 1.34b

Hale & Tempest India Pharma Market Projections Source IPA

Hale & Tempest FDA Approved Manufacturing Sites source FDA

Hale & Tempest USA DMFs ex India

Hale & Tempest USA DMFs ex China Source FDA

Hale & Tempest India represents 50% of USA ANDAs

Hale & Tempest Top Generics Companies Source Generics Bulletin June 2009

Hale & Tempest Middle Size Generics Companies Source Generics Bulletin June 2009

Hale & Tempest WHO Pre Qualified Products

Hale & Tempest Discovery Services in India

Hale & Tempest Early discovery leads from USA, Europe or Singapore Molecular optimisation from India Toxicology from China, Central Europe, Singapore Electronic Data Capture India API Manufacture India Drug Formulation Manufacture India, USA Phase 1 Clinical Trials Europe Phase 2,3 heavy use of India Corporate back office India India and Global Drug Development

Hale & Tempest India R&D Investment

Hale & Tempest Thank You